Protein aggregation has been recognized as one of the major challenges in the
development and commercialization of successful protein-based drug products because of …

Protein pharmaceuticals have become a significant class of marketed drug products and are
expected to grow steadily over the next decade. Development of a commercial protein …

Solutions of different polymers in the same solvent are incompatible as a rule and show
phase separation when they are mixed. H incompatibility is also to be observed in systems …

Viscosity of protein solution is one of the most troublesome issues for the high-concentration
formulation of protein drugs. In this review, we summarize the practical methods that …

It is well recognized that protein product development is far more challenging than that for
small‐molecule drugs. The major challenges include inherent sensitivity to different types of …

Colloidal liquids interacting with short range attraction and long range repulsion, such as
proposed for some protein solutions, have been found to exhibit novel states consisting of …

In the last few decades, the controlled colloidal assembly was adopted as a new modelling
technology for the study of the crystallization mechanism. In colloidal systems, the movement …

Purpose To explain the effects of cationic amino acids and other co-solutes on the viscosity,
stability and protein-protein interactions (PPI) of highly concentrated (≥ 200 mg/ml) …

Multiple advanced formulations and drug delivery systems (DDSs) have been developed to
deliver protein-based biotherapeutics via the subcutaneous (SC) route. These …

Purpose To explain the effects of the osmolyte proline on the protein-protein interactions
(PPI), viscosity and stability of highly concentrated antibody solutions in contrast to other …